Veru Balance Sheet Health
Financial Health criteria checks 4/6
Veru has a total shareholder equity of $45.2M and total debt of $9.7M, which brings its debt-to-equity ratio to 21.5%. Its total assets and total liabilities are $71.8M and $26.6M respectively.
Key information
21.5%
Debt to equity ratio
US$9.73m
Debt
Interest coverage ratio | n/a |
Cash | US$34.74m |
Equity | US$45.21m |
Total liabilities | US$26.59m |
Total assets | US$71.80m |
Recent financial health updates
Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?
Jan 13Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?
Sep 26Recent updates
What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You
Jul 17Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
May 31The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%
Jan 09Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)
Aug 16Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors
Apr 17Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price
Feb 14Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?
Jan 13Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically
Nov 13Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict
Oct 17Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?
Sep 26Veru FDA AdCom meeting for COVID-19 therapy postponed
Sep 19Veru: A Good Combination Of A Stable Business And Growth Opportunities
Sep 13Veru surges 11% as FDA sets AdCom meeting to review COVID-19 therapy
Sep 07Veru sheds 13% to end rally as director sells shares
Aug 18Veru Q3 2022 Earnings Preview
Aug 10Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer
Aug 03Veru eligible for expedited review in U.K. for COVID-19 therapy
Jul 25Veru: The Signs Seem To Point To An EUA For Sabizabulin
Jul 13Veru phase 3 results of sabizabulin for COVID-19 published in NEJM
Jul 06Veru: On Right Track For FDA EUA Submission
May 27Financial Position Analysis
Short Term Liabilities: VERU's short term assets ($45.1M) exceed its short term liabilities ($9.6M).
Long Term Liabilities: VERU's short term assets ($45.1M) exceed its long term liabilities ($17.0M).
Debt to Equity History and Analysis
Debt Level: VERU has more cash than its total debt.
Reducing Debt: VERU's debt to equity ratio has reduced from 32.5% to 21.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VERU has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: VERU has less than a year of cash runway if free cash flow continues to reduce at historical rates of 47% each year